Switzerland: Comphya convertible stimulates start of pilot clinical trials

Comphya CaverSTIM

Comphya, the developer of the first neuromodulator to treat erectile dysfunction (ED), has raised CHF850,000 (US$917,000) in a convertible loan. It brings the total amount of funds raised to CHF5.1m. The financial round included investment from existing shareholders and additional investors. Praxis Spinal Cord Institute, a non-profit organization, also committed to participate. Praxis is an…

You must be a HMI Subscriber to view this content.

Subscribe Now »